Lauder/Puig Deal Talks End, E.l.f. Beauty Slashes Prices; Beauty Biz Roundup
Estee Lauder reports it has ended talks with Spanish firm Puig Brands SA to combine the businesses. Separately, e.l.f. Beauty Inc. reports strong fiscal fourth quarter and fiscal year sales.
HBW Insight - May 25, 2026

QT Imaging CEO: AI Cannot Recover What Mammography Never Captured
The FDA's breast density rule reached 40 million women – but stopping at disclosure left a structural gap no technology has yet filled. QT Imaging's CEO explains why the real barriers are capacity, reimbursement and a screening system never built for what comes next.
Medtech Insight - May 25, 2026

Sobi’s Arthrosi Buy Pays Off With Phase III Gout Drug Win
The oral selective URAT1 inhibitor pozdeutinurad developed by Arthrosi, which Sobi bought for $950m up front, significantly reduced serum uric acid in gout patients.
Scrip - May 25, 2026

EU Agreement On Trade Deal With US Means More Predictable Transatlantic Relations For Pharma
Regulation underpinning the EU application of the EU-US trade deal now includes a safeguard mechanism and sunset clause that offer extra security for pharmaceutical companies.
Pink Sheet - May 25, 2026

Gilead’s Hepcludex Gets FDA Nod For HDV, Four Years After CRL
Although Hepcludex has been approved in the EU since 2020, Gilead needed five and half years to gain US approval as the first drug for hepatitis D, a severe comorbidity of hepatitis B.
Scrip - May 25, 2026

Ebola Outbreak Drives Medical Device Makers to Mobilize PCR Tests and Blood-Filtration Technology
20/20 Biolabs, Co-Diagnostics and Aethlon mobilize PCR assays, lab capacity, and blood-filtration technology against the Bundibugyo strain, as world governments update their threat assessments and responses.
Medtech Insight - May 25, 2026

Aurobindo On US Atopic Dermatitis Drug Launch, Biologics Manufacturing For Merck
Aurobindo revealed plans to launch an Otsuka-licensed NCE to treat atopic dermatitis in the US in the second quarter of FY27 and the strategy behind significant capacity build for anchor partner Merck's biologics.
Scrip - May 25, 2026

AstraZeneca, Daiichi Gain Edge On First-line Triple Negative Breast Cancer With Datroway Approval
Datroway’s first-line TNBC approval strengthens competition in the TROP2 ADC market as rivals including Gilead advance therapies into earlier treatment settings.
Scrip - May 25, 2026

Biopharma M&A — Rothschild’s Bal On Dry Powder, PE Play and India’s Unique Calculus
Rothschild & Co India MD discusses the M&A outlook for biopharma amid global volatility, why biotechs are warming up to deals, PE appetite in India, and how the next generation of domestic family-controlled firms appears more pragmatic about value-creating opportunities.
Scrip - May 25, 2026

MedTech Forum 2026 Interview: Bring The Innovation Launch Pad Back To Europe
MedTech Europe CEO Oliver Bisazza set out his hopes and aims for EU industry and markets during the MedTech Forum 2026 against a backdrop of cautious optimism in regulatory and strategy circles now the MDR/IVDR revision is getting EU co-legislator attention. Elsewhere, there remains work to do.
In Vivo - May 25, 2026

MS Pharma Boosts Biosimilar Ambitions With Minority Equity Investment
Olayan Financing Company’s minority stake gives MS Pharma both the cash and the local network it needs to turn an ambitious MENA biosimilar strategy into real market presence in 2026.
Generics Bulletin - May 25, 2026

Fresenius Celebrates US Federal Win On Ustekinumab
A federal contract in the US is set to bolster Fresenius Kabi’s Biopharma business, which grew by a quarter – and by 34% at constant currencies – in the first quarter of 2026, boosted by gains for tocilizumab and denosumab.
Generics Bulletin - May 25, 2026

Accord’s Burden Moves Up To Chair At Medicines UK
UK generics and biosimilars association Medicines UK has announced the appointment of Accord’s Paul Burden as its new chair. He takes over the role from Sandoz’s Diane Di Gangi-Trench who will stay on for a further year as vice-chair.
Generics Bulletin - May 25, 2026

Stock Watch: Bayer’s First-Quarter Rally And CSL’s Plunge Both Miss The Real Story
Bayer’s first-quarter crop science rally impressed the press for the wrong reasons. CSL’s surprise announcement, on the other hand, had been a long time coming, and an 11% stock drop reflected it.
Scrip - May 25, 2026

Quick Listen: Scrip’s Five Must-Know Things
In this week's episode: industry grapples with MFN fallout; rapid early trials fuel China deals; AbbVie looks to grow in neuroscience; is circular DNA the next big thing?; and a flunk for Regeneron’s fianlimab.
Scrip - May 25, 2026